These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 37163718)

  • 1. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
    Desai NV; Tan AR
    JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
    Litton JK; Beck JT; Jones JM; Andersen J; Blum JL; Mina LA; Brig R; Danso M; Yuan Y; Abbattista A; Noonan K; Niyazov A; Chakrabarti J; Czibere A; Symmans WF; Telli ML
    Oncologist; 2023 Oct; 28(10):845-855. PubMed ID: 37318349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
    Chen Z; Wang X; Li X; Zhou Y; Chen K
    J Int Med Res; 2021 Feb; 49(2):300060521991019. PubMed ID: 33541181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
    Tazzite A; Jouhadi H; Benider A; Nadifi S
    Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The landscape of systemic therapy for early stage triple-negative breast cancer.
    Lu JY; Alvarez Soto A; Anampa JD
    Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
    Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
    Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy.
    Wang X; Hu N; Cui L; Si Y; Yue J; Zheng F; Kang Y; Yuan P
    Curr Cancer Drug Targets; 2022; 22(6):530-536. PubMed ID: 35156571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
    Ring A; Kilburn LS; Pearson A; Moretti L; Afshari-Mehr A; Wardley AM; Gurel B; Macpherson IR; Riisnaes R; Baird RD; Martin S; Roylance R; Johnson H; Ferreira A; Winter MC; Dunne K; Copson E; Hickish T; Burcombe R; Randle K; Serra V; Llop-Guevara A; Bliss JM; Turner NC
    Clin Cancer Res; 2023 Dec; 29(23):4751-4759. PubMed ID: 37773077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
    Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
    PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
    Eikesdal HP; Yndestad S; Elzawahry A; Llop-Guevara A; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Vagstad G; Venizelos A; Minsaas L; Leirvaag B; Gudlaugsson EG; Vintermyr OK; Aase HS; Aas T; Balmaña J; Serra V; Janssen EAM; Knappskog S; Lønning PE
    Ann Oncol; 2021 Feb; 32(2):240-249. PubMed ID: 33242536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
    Song W; Tang L; Xu Y; Xu J; Zhang W; Xie H; Wang S; Guan X
    Sci Rep; 2017 Feb; 7():42319. PubMed ID: 28176879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.